OMPTA LptA Thanatin Program
Multidrug-Resistant Gram-negative Infections
Pre-clinicalActive
Key Facts
About Spexis
Spexis AG is a publicly traded biopharma focused on discovering and developing novel macrocyclic therapeutics for rare diseases and cancer. Its strategy is built upon two proprietary technology platforms: a Macrocycle Platform for undruggable targets and an OMPTA Platform for antibiotic-resistant Gram-negative infections. The company's most advanced program, ColiFin®, is an approved inhaled therapy for cystic fibrosis, positioning Spexis with a late-stage asset while advancing earlier clinical and pre-clinical candidates. Spexis is actively seeking development and commercialization partners to maximize the value of its pipeline and platforms.
View full company profileTherapeutic Areas
Other Multidrug-Resistant Gram-negative Infections Drugs
| Drug | Company | Phase |
|---|---|---|
| OMPTA LPS & BamA Program | Spexis | Pre-clinical |
| Program targeting Enterobacteriaceae | Telum Therapeutics | Pre-clinical |
| Program targeting Acinetobacter baumannii | Telum Therapeutics | Pre-clinical |
| Program targeting Pseudomonas aeruginosa | Telum Therapeutics | Pre-clinical |
| BAL2420 | Basilea Pharmaceutica | Phase 1 |